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ABSTRACT 
60 Patients were selected for the clinical study in 3 groups and 20 patients were in each group. The quality of life improved with the Prostowin Vati 
and Ksheerabala oil Vasti with the reduction in symptom score (IPSS and DPSS), Residual urine, Micturition time and improvement in Average flow 
rate. Old persons refuse operative treatment for their BPH symptoms and seeking a safe and effective treatment for easy life. In this situation the 
medicinal treatment may play an important role.  
Keywords: Straining, Intermittency, International prostate symptom scoring system (IPSS), Danish Prostate Symptom scoring system (DPSS), 
Residual 
INTERODUCTION 
Benign prostatic hyperplasia is a disease of old male person when 
their hair becomes gray and scanty and when a white zone is formed 
at the margin of the cornea. This disease refers to the adenamotous 
enlargement of the periurethral prostate gland, promoting 
obstruction of the urethra and bladder opening. As men age, the 
prostate gland increases in size, making BPH one of the most 
common age-related conditions in men. The enlarged gland puts 
pressure on the urethra, acting like a partial clamp and thus causing 
numerous urinary symptoms. BPH is a progressive disease, but it 
does not usually cause problems until late in life. 
B.P.H. is a condition intimately related to ageing and most frequently 
seen in men in 7th, 8th, 9th decade but also occurs in 6th and even 5th 
decade of life. International surveys have found a high prevalence of 
moderate to severe obstructive symptoms in men over 50, which 
increase with age. Symptoms of BPH vary in severity and include 
frequent urination, nocturia (excess urination at night), urinary 
urgency or hesitancy, painful and difficult urination (dysuria) and 
incomplete urination, Inflammation and infection of prostatic tissues 
may also be present.  
izLrqr 'kks/k izcU/k esa 60 jksxh;ksa ij rhu oxksZ ¼izR;sd oxZ esa 20 jksxh½ esa 
izksLVkfou oVh ,oa {khjcyk rSy dk fpfdRlkRed v/;;u fd;k x;kA  
izksLVkfou oVh ,oa {khjcyk rSy jksfx;ksa ds vkkbZ- ih- ,l- ,l- vkSj Mh- 
ih- ,l- ,l- Ldksj dks de djus es] ew=kkof̀Ùk de djus esa vkSj  vo’ks"k 
ew= dh ek=k de djus esa ,oa izksLVsV xzfUFk dk Hkkj de djus esa 
ykHknk;d gSA o)̀koLFkk esa 'kY; deZ djkus esa Hk; ,oa 'kkjhfjd nqcZyrk] 
vkfFkZd vleFkZrk ,oa vk/kqfud lekt esa o`)ks ds izfr vlg;ksx dks /;ku 
esa j[krs gq, v"Bhyk o`f) esa vkS"k/k izksLVkfou oVh ,oa {khjcyk rSy dk 
iz;ksx vfrykHknk;d gSA 
NEED AND SIGNIFICANT 0F PRESENT RESEARCH WORK 
In modern surgical therapy for BPH, the patient may suffer from 
following complications: 
Retrograde ejaculation- 65% 
Erectile impotence - 5% 
Clot retention, stricture, incontinence, infection, perforation of 
prostatic capsule, haemorrhage are other complications. 
Problems with urination can be very distressing and severely affect 
quality of life, although individual response to these symptoms 
varies widely. Some men can tolerate very uncomfortable sensations 
of abnormal urination, while other men seek relief from mild 
symptoms. Men are more apt to tolerate voiding symptoms 
(intermittent flow, hesitancy before urinating) and seek help for 
storage symptoms (urgency, frequency, urination at night). Voiding 
symptoms, however, may indicate an obstruction blocking the 
bladder, which if extensive can severely reduce urine flow and cause 
other complications. Due to these complications and ignorance of 
operative therapy in old age, old persons refuse operative treatment 
for their BPH symptoms and seeking a safe and effective treatment 
for easy life. In this situation the medicinal treatment may play an 
important role.  
Aims and Objective 
The main aims and objective of present study were as follow- 
 Evaluation of efficacy of an Ayurvedic formulation 
Prostowin vati in the management of BPH.  
 Evaluation of efficacy of Vata Samak Vasti (Ksheerabala 
taila) treatment in the management of BPH. 
 Evaluation of efficacy of combined therapy in BPH based 
on various parameters. 
The other objectives of the present clinical trial were as follow- 
 To reduce the severity of symptom of BPH patient with 
Ayurvedic medicine 
 To break the pathogenesis of BPH on modern concept 
with Ayurvedic formulation 
 To improve the quality of life of BPH patients 
Selection of drug 
The drug selected for the clinical study was with multifactorial 
action.  
Prostowin vati was deigned and prepared for the management of 
Benign Prostatic Hyperplasia with consideration of following 
qualities - 
 Vrishya and Rasayana properties 
 Diuretic properties 
 Anti-inflammatory and Antispasmodic properties 
 Vata and Kapha samak properties 
 5-α reductase inhibitor activity 
 Contents of Prostowin vati- 
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S.N. Name of 
drug 
Bot. Name Family  Part 
used 
1. Erand Ricinus 
communis 
Euphorbiaceae  Root  
2. Bal haritaki Terminalia 
chebula 
Combretaceae  Fruit  
3. Punarnava Boerhavia 
diffusa 
Nyctaginaceae  Root  
4. Varuna Crataeva 
novella 
Capparidaceae  Bark  
5. Kapikachhu Mucuna 
prurita 
Leguminoceae  Seed  
6. Amalaki  Emblica 
officinalis 
Eurphobiaceae Fruit  
7. Ashwagandh  Withania 
somnifera 





Cucurbitaceae  Seed  
9. Trapush  Cucumis 
sativus 
Cucurbitaceae  Seed  
10. Shilajatu  Asphatinum 
punjabinum 
 Niryas  
11. Yava  Foeniculum 
vulgare 
 Kshara  
 ksheer-bala oil was used for vasti treatment in present study.  
Name of drug Bot. name Family  Part used 
Bala  Sida cardifolia Malvaceae Whole plant  
Taila  Sesamum indicum Pedaliaceae  Seed oil  
Godugdha Cow milk   
- Protowin vati and Ksheerbala oil was prepared in the pharmacy 
of national institute of Ayurveda, Jaipur 
MATERIAL AND METHODS 
Inclusion criteria 
Patients above the age of 40 years 
Patients having benign growth only 
Patients unfit for surgery 
BOO due to BPH only 
Exclusion criteria 
Patients having acute retention and severe UTI, Diabetes, 
Prostatic carcinoma, Prostatitis, C.A. bladder, Neurogenic bladder, 
Stricture of urethra, Vesicle calculus 
Criteria of grading the patients 
Grade I - If the weight within 29 gm of Prostate gland. 
Grade II  - 29 - 59 gm. 
Grade III - 59-89 gm. 
Grade IV - More than 89 gm. 
Grouping-       All 60 patients were divided in 3 groups - 
Group –A - Patients treated with Prostowin vati only. 
Group-B - Patients treated with Ksheer Bala taila vasti only. 
Group-C- Patients treated with combined (Prostowin vati and 
Ksheer Bala taila vasti) therapy. 
Dose of drug   :2 tab. tid 
Dose of oil for vasti                      :50 ml / day 
Duration of drug administration: Three months 
Duration of vasti treatment  : One month 
Subjective parameters 
 Over symptoms like Incomplete evacuation, Frequency, 
Intermittency, Urgency, Weak urine stream, Straining and 
Nocturia 
 International prostate symptom scoring system(IPSS)  
 Danish Prostate Symptom scoring system(DPSS)  
Objective parameters-  
 Digital rectal examination 
 USG (KUB region)-  
a) Change in prostate volume (Weight) 
b) Residual urine 
 Average flow rate  
 Micturition time 
Prostate weight 
Weight of prostate (in gm.) 0.55  Length (D1)  Width (D2)  
Height (D3) 
Residual urine 
Residual urine (ml) Length (D1)  Width (D2)  Height (D3)/2 
Measurement of Average flow rate and Micturition time 
Average flow rate (ml/second)=Total urine passed (in ml) 
          Total Micturition time (seconds) 
ESTIMATION OF RESIDUAL URINE 
 
PROCEDURE OF VASTI KARMA 
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Summarized result on subjective parameters of group-A 
Parameters   Mean B.T. Mean A.T. % Improv. t- value p-value 
Incomplete evacuation 3.55 1.6 54.93 10.5634 < 0.001 
Frequency 3.25 1.45 55.38 9.6567 < 0.001 
Intermittency 2.80 1.15 58.93 7.4694 < 0.001 
Urgency 3.05 1.40 54.10 9.9039 < 0.001 
Weak stream 3.45 1.70 50.72 12.2549 < 0.001 
Straining 3.80 1.75 53.95 11.1051 < 0.001 
Nocturia 3.30 1.60 51.52 8.2324 < 0.001 
IPSSS 23.20 10.65 54.10 19.7825 < 0.001 
DPSS(Symptoms severity) 20.80 9.60 53.85 18.244 < 0.001 
DPSS(Degree of Bothering) 19.25 9.10 52.73 13.8889 < 0.001 
In group-A the maximum relief was observed in intermittency symptom (58.93%) and minimum in symptom of weak stream (50.72%). The overall 
IPSS improvement was 54.10%. The percentage relief in DPSS (symptom severity) was 53.85% and in degree of bothering was 52.73%. The 
improvements were highly significant in all symptoms 
Summarized result on Objective parameters of group-A 
Parameters   B.T. A.T. % Improv. t- value p-value 
Weight 38.2 33.25 12.95 6.3789 < 0.001 
Residual urine 107.5 52.25 51.40 8.8403 < 0.001 
Voided volume 191.75 218.75 14.08 9.9111 < 0.001 
Micturition time 55.45 38.15 31.9 11.0571 < 0.001 
Average flow rate 3.47 5.89 69.4 14.64 < 0.001 
In all objective parameters of group-A, the maximum percentile improvement was noticed in average flow rate (69.4%) followed by in Residual 
urine (51.40%).  
Summarized result on subjective parameters of group-B 
Parameters   B.T. A.T. % Improv. t- value p-value 
Incomplete evacuation 3.4 2.1 38.24 7.9365 < 0.001 
Frequency 3.30 2.00 39.39 7.2544 < 0.001 
Intermittency 3.15 1.65 47.62 7.8125 < 0.001 
Urgency 3.10 1.50 51.61 9.4899 < 0.001 
Weak stream 3.15 1.65 47.62 7.549 < 0.001 
Straining 3.10 1.80 41.94 7.2545 < 0.001 
Nocturia 2.80 1.70 39.29 8.9069 < 0.001 
IPSSS 22  12.4 43.64 25.751 < 0.001 
DPSS(Symptoms severity) 19.70 12.70 35.53 16.3094 < 0.001 
DPSS(Degree of Bothering) 18.10 11.45 36.74 11.6157 < 0.001 
In group-B the maximum relief was observed in urgency symptom (51.61%) and minimum in symptom of incomplete evacuation (38.24%%).The 
overall IPSS improvement was 43.64%. The percentage relief in DPSS (symptom severity) was 35.53% and in degree of bothering was 36.74%. The 
improvements were highly significant in all symptoms. 
Summarized result on Objective parameters of group-B 
Parameters   B.T. A.T. % Improv. t- value p-value 
Weight 41.7 38.6 7.43 5.9319 < 0.001 
Residual urine 109.25 63.75 41.65 10.2112 < 0.001 
Voided volume 199.75 224.75 12.52 11.036 < 0.001 
Micturition time 58 44.55 23.19 11.6683 < 0.001 
Average flow rate 3.48 5.09 46.55 15.3419 < 0.001 
In all objective parameters of group-B, the maximum percentile improvement was noticed in average flow rate (46.55%) followed by in Residual 
urine (41.65%). 
Summarized result on subjective parameters of group-C 
Parameters   B.T. A.T. % Improv. t- value p-value 
Incomplete evacuation 3.4 1.1 67.65 12.8348 < 0.001 
Frequency 2.85 0.90 68.42 9.233 < 0.001 
Intermittency 2.75 0.95 65.45 10.4834 < 0.001 
Urgency 2.95 0.90 69.49 9.7064 < 0.001 
Weak stream 3.00 0.90 70.00 11.0178 < 0.001 
Straining 3.00 0.95 68.33 8.7308 < 0.001 
Nocturia 3.00 1.10 63.33 8.3224 < 0.001 
IPSSS 20.95 6.8 67.54 23.4349 < 0.001 
DPSS(Symptoms severity) 18.80 7.40 60.64 23.8544 < 0.001 
DPSS(Degree of Bothering) 17.70 7.05 59.71 21.5805 < 0.001 
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In group-C the maximum relief was observed in weak stream symptom (70.00%) and minimum in symptom of nocturia (63.33%). The overall IPSS 
improvement was 67.54%. The percentage relief in DPSS (symptom severity) was 60.64% and in degree of bothering was 59.71%. The 
improvements were highly significant in all symptoms. 
Summarized result on Objective parameters of group-C 
Parameters   B.T. A.T. % Improv. t- value p-value 
Weight 37.85 28.1 25.76 16.0104 < 0.001 
Residual urine 117.5 47 60 15.0451 < 0.001 
Voided volume 203 249 22.66 15.3129 < 0.001 
Micturition time 60.1 41.25 31.36 13.5758 < 0.001 
Average flow rate 3.41 6.04 77.13 18.2408 < 0.001 
In all objective parameters of group-C, the maximum percentile improvement was noticed in average flow rate (77.13%) followed by decrease in 
Residual urine (60%). 
The subjective and objective parameters were further analyzed on the basis of prakriti of patients.  
OBSERVATION AND RESULT 
IPSS 
The mean IPSS was maximum in group-A of 60-69 yrs age group 
(23.38) and minimum in 70-above age group (23). The maximum 
improvement in group-A was noticed in 70-above age group 
(57.26%). 
In group-B the maximum improvement in IPSS was also in 70-above 
age group (44.75%). The percentile relief in IPSS increased as age 
increases in this group. 
Where as in group-C maximum IPSS improvement was observed in 
50-59 yrs age group (70.93%). Particularly in this group, decrease in 
percentile relief in IPSS was observed as age increases. 
Weight of Prostate 
 Most of the patients of all groups were with second grade of BPH. 
The maximum weight was 54 g and minimum was 25 g. the prostate 
weight reduction was maximum in 50-59 yrs of group-C (28.48%). 
As the age increases less effect of therapy was noticed in group-C i.e. 
60-69yrs-26.77% and in 70-above- 22.21% 
Residual Urine 
64.17% relief was noticed in group-C patients of 60-69 yrs age 
group. The minimum relief in residual urine of group-C was in 70-
above age group (55.07%). In 50-59 yrs age group the maximum 
relief was observed in group-A patients (57.82%) and minimum 
relief was observed in group-B patients of 60-69 yrs age group 
(39.34%). 
Micturition Time 
In all groups, before treatment mean micturition time ranges from 
53-60 sec. whereas after treatment it was between 37-46 sec. The 
maximum percentile reduction in micturition time was in group-A of 
50-59 yrs (33.52%) and minimum was in same age group of group-B 
(20.84%). 
Average flow rate 
The average flow rate was almost same in all groups and age groups 
but maximum mean value observed in group-A of 60-69 yrs 
(3.63ml/sec). 
The maximum percentile increase in average flow rate was in group-
C patients- 81.37, 76.48 and 75.73% according to increasing age 
group. 
The group-B patients showed nearly same percentile relief in 50-59 
and 60-69 yrs age groups. 70-above age group patients of group-B 
get maximum relief (54.44%). 
The incidence and results are analyzed on the basis of patient’s 
prakriti. 
IPSS 
The maximum mean IPSS observed in group-A was of kaphaja 
prakriti (24.6), in group-B and C of pittaja prakriti 24.5 and 21.17 
respectively. So all groups showed severe symptom according to 
IPSS. 
 
The pittaja prakriti patients got less relief in all the groups especially 
in group-B (37%). 
Weight of Prostate 
The maximum percentile weight reduction was noticed in group-C of 
vatika patients (28.65%). In group-A maximum relief in kaphaja 
patients (19.8%) and minimum in paittika patients (9.92%). The 
group-B patients relieved less in this contrast. Kaphaja patients of 
group-B got only 2.4% reduction whereas pittaja patients with 
10.14% and vatika with 7.57% in weight reduction. 
Residual urine 
The mean residual urine reduced well in group-C patients. The 
maximum relief observed in kaphaja prakriti patients of group-C 
(66.27%) followed by vatika patients (63.16%). Whereas in group-A 
vatika patients got maximum relief of 57.98% followed by kaphaja 
prakriti (51.58%). 
The trend of residual urine reduction of group-C was observed in 
group-B also. Here vatika patients got 49.34%, kaphaja patients-
40% and pittaja prakriti patients got 24.13% relief. 
Micturition Time 
The group-A patients showed maximum reduction in micturition 
time of vatika prakriti patients (36.91%) and vatika patients of 
group-C got 35.21% relief, which was maximum relief in group-C of 
all prakriti. 
Vatika patients of group-B got 28.13% relief, which was maximum in 
this group and minimum was of kaphaja prakriti patients 17.99% 
only. 
Average flow rate 
Vatika patients of group-C showed maximum increase in average 
flow rate 88.05% in all groups and pittaja patients of this group 
relieved 63.10% whereas kaphaja prakriti patients got 71.46% 
relief. 
In group-A vatika patients relieved 83.57% in average flow rate 
followed by kaphaja patients (57.44%). In group-B patients 
maximum relief was noticed in pittaja patients (36.62%).  
CONCLUSION 
In present clinical study Evaluation of efficacy of an Ayurvedic 
formulation Prostowin vati and Ksheerabala oil Vasti in the 
management of BPH had done. The conclusions of study are as 
follow- 
The BPH is a disease of elderly person and more prevalent in vatic 
and kaphaja individuals. The development of symptoms like 
incomplete evacuation, frequency, hesitancy, weak stream, nocturia 
etc. make the life of the sufferer very uncomfortable desiring 
immediate remedy for that. 
The non-invasive and non-surgical therapy (Prostowin vati and 
Ksheerabala oil Vasti) suggested in present study has provided 
better non-hormonal alternative therapy to the BPH patients 
without any adverse effect.  
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The Prostowin vati formulation selected on the basis of pathogenesis 
involved in the BPH is very effective in reducing the symptoms of 
BPH. 
The drug show better results with the Vatasamaka vasti treatment 
especially in weight reduction of prostate may be due to some 
hypoplastic effects. 
The quality of life improved with the Prostowin Vati and 
Ksheerabala oil Vasti with the reduction in symptom score (IPSS and 
DPSS), Residual urine, Micturition time and improvement in Average 
flow rate. 
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